Triple-Threat attack on tough blood cancers shows promise
NCT ID NCT04140487
Summary
This study is testing a new combination of three drugs—azacitidine, venetoclax, and gilteritinib—for adults with certain aggressive blood cancers that have returned or not responded to treatment. The main goals are to find the safest dose and see if adding gilteritinib helps patients achieve remission better than the standard two-drug therapy. The trial is for people whose cancer has a specific genetic change called an FLT3 mutation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.